11/4/2026

speaker
Conference Operator
Operator

Good afternoon, ladies and gentlemen, and welcome to the CIRA Prognostics Third Quarter 2026 Financial Results. At this time, all lines in a listen-only mode. Following the presentation, we'll conduct a question and answer session. Instructions will be provided at that time for you to queue up for questions. If anyone has any difficulties hearing the conference, please press star zero for operator assistance at any time. I would like to remind everyone that this call is being recorded on Wednesday, November 4th, 2026. I would now like to turn the call over to Jennifer Zibuda, Head of Investor Relations. Please go ahead.

speaker
Jennifer Zibuda
Head of Investor Relations

Thank you, Operator. Welcome to SARA Prognostics' third quarter 2026 earnings conference call. Earlier today, SARA reported financial results for the quarter which ended September 30th, 2026. Joining me on today's call are Zhenya Lindgardt, President and Chief Executive Officer, Lee Anderson, Chief Commercial Officer, Tiffany Inglis, Chief Medical Officer, and Scott Gleason, Chief Financial Officer. Following our prepared remarks, we will open the call for questions. A copy of today's earning release can be found on the investor section of our website at sarah.com, and a replay of this webcast will also be available. We have also posted an accompanying slide deck presentation pertaining to today's earnings call on the events section of our investor relations website. Before we begin, please note that today's discussion will include projections or forward-looking statements about events and circumstances that have not yet occurred, including regarding our business, future financial results and performance, and market opportunities. These statements are based on our current expectations and are subject to risk factors and uncertainties that could cause actual results to differ materially and adversely from these expectations and forward-looking statements. Please refer to our filings with the Securities and Exchange Commission, including our most recent forms 10-K, 10-Q, and 8-K for important information regarding these risk factors. With that, I will turn the call over to Zhenya.

speaker
Zhenya Lindgardt
President and Chief Executive Officer

Good afternoon, everyone, and thank you for joining us today. At CERO, we believe we're building something truly unique in healthcare. We have developed one of the most highly validated advanced lab tests in history, addressing one of the most important and underserved challenges in medicine, preterm birth. The preterm test has demonstrated the ability to identify high-risk pregnancies early and drive meaningful improvements in outcomes for mothers and babies. We're no longer simply an evidence generation story. We're actively transitioning into the commercialization phase of our journey with the goal of establishing preterm as a foundational component of prenatal care. The opportunity remains largely untapped with no effective standard for broad population screening of preterm birth risk. As a result, we believe there is the potential to create a new category in prenatal care and address one of the largest unmet needs in healthcare while driving substantial long-term value for shareholders. The third quarter represented a significant step forward in that journey. Following publication of the landmark prime study and the addition of highly experienced commercial leaders to our management team, we saw strong momentum in the third quarter. Compared to the first quarter of this year, the number of physicians ordering preterm nearly tripled while test volumes increased approximately fivefold. We believe these results provide early evidence that the combination of compelling clinical data and focused commercial execution can drive meaningful adoption of preterm in real-world clinical practice. We also continue to make significant progress on reimbursement as we execute a multi-tiered strategy to expand coverage across both state Medicaid programs and commercial insurers. We now have seen a second major Medicaid state cover the test. Florida has established coverage for Medicaid beneficiaries and has added the preterm test as a covered service under the state biomarker testing law. Additionally, pricing has been established on the state's fee schedule. With nearly 90,000 Medicaid births and approximately 4 million Medicaid lives, Thank you. Thank you. These milestones demonstrate the growing recognition of the clinical and economic burden of preterm birth and the need for solutions that improve outcomes while also reducing healthcare costs. Supported by strong clinical utility data, compelling health economic evidence, increasing provider engagement, and growing public policy focus on maternal health, we believe we're well positioned to accelerate adoption of preterm and advance our long-term vision of establishing the test as a standard component of prenatal care. While our immediate focus remains on executing in the United States, our long-term vision is to build a truly global company. As evidence of our progress, we continue to advance our international strategy and remain on track to pursue CE-MARC approval for preterm global, our kit-based version of preterm in 2027. In parallel, we are engaged in active discussions with potential commercial partners, including both laboratory and in vitro diagnostic companies, as we evaluate opportunities to expand access to preterm in markets outside the United States. We have successfully completed our registration study and are working with our notified body on our CE mark submission. This represents an important milestone in our growth strategy. The addressable market opportunity outside the United States is at least as large as our domestic market. We believe these efforts have the potential to establish a meaningful new growth engine and further advance our mission of improving outcomes for mothers and babies around the world. As we go forward, we're actively focused on executing on three critical strategic imperatives to achieving our long-term goals. These include first, demonstrating a repeatable and scalable commercial model. Our priority is to validate and scale our commercial model in reimbursed markets. With coverage now established in Illinois and Florida, we have two significant opportunities to demonstrate how strong clinical evidence, reimbursement, and focused field execution can drive adoption. We believe success in these markets will not only support near-term growth, but also establish a playbook for expansion into additional geographies and validate the scalability of our commercial strategy. Next, converting leading clinical evidence into expanding reimbursement and market access. Our second priority is to convert our best in class evidence base into broader reimbursement coverage and increase adoption of preterm. We're executing a comprehensive market access strategy designed to expand coverage across both Medicaid and commercial payer channels while establishing the foundation for long-term growth. We believe the growing national focus on maternal health creates a favorable environment for additional state Medicaid coverage mandates in 2027 and beyond. We're actively supporting professional guideline inclusion based on the strong clinical utility and health economic outcomes demonstrated through PRIME. We're also evaluating opportunities to take advantage of existing legislative Actions and Laws Supporting Improved Maternal and Neonatal Care, which will collectively impact nearly 1.4 million births each year. We believe these efforts position us to expand access to preterm, strengthen reimbursement, and move closer to our goal of making preterm birth risk assessment a routine component of prenatal care. And finally, driving capital efficient growth. Our third priority is to maintain a disciplined approach to capital allocation and ensure that every dollar we invest is directed towards our highest return opportunities. As part of our 2027 planning process, we are carefully evaluating our cost structure, identifying opportunities to improve efficiency and streamline operations, and reallocating resources towards initiatives that directly support commercial growth and market expansion. Our goal is to maximize return on invested capital while building the capabilities, infrastructure, and market presence necessary to support the next stage of our growth. To provide more detail on our progress against these strategic priorities, I will now turn the call over to our Chief Commercial Officer, Lee Anderson, to discuss our commercial execution. Lee?

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation